Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas
A case report. Rosiglitazone treatment was highly effective yet had to be terminated
Author
Summary, in English
The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.
Department/s
- Diabetes - Clinical Obesity
- Translational Muscle Research
Publishing year
2002
Language
Swedish
Pages
407-410
Publication/Series
Läkartidningen
Volume
99
Issue
5
Document type
Journal article
Publisher
Swedish Medical Association
Topic
- Endocrinology and Diabetes
- Nutrition and Dietetics
Status
Published
Research group
- Diabetes - Clinical Obesity
- Genomics, Diabetes and Endocrinology
ISBN/ISSN/Other
- ISSN: 0023-7205